ClinicalTrials.gg
WithdrawnNCT03554707Updated May 8, 2026

SGT-53 in Children With Recurrent or Progressive CNS Malignancies

An Early Phase 1 interventional study of SGT-53 and Radiation in Childhood CNS Tumor, sponsored by SynerGene Therapeutics, Inc.. Withdrawn at 1 site in United States. Open to participants aged 1 Year to 21 Years. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by SynerGene Therapeutics, Inc. · Early Phase 1, Interventional, and Treatment

Why this study was withdrawn
The grant intended to support this trial as ultimately not funded. This trial was not initiated,. No patients were enrolled.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
1 Year to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing irinotecan in Central Nervous System Neoplasms — 1 open to participants now, 1 under way, none of them phase 3. Irinotecan · Central Nervous System Neoplasms.

Enrollment
17th of 17
0 · median 36
Started
2022
the only one that year
Phase 1
10 of 23
none open now
Registered
22nd of 23
by date

Among the 23 studies testing irinotecan in Central Nervous System Neoplasms, this one is the 17th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2022, is one of 10 in phase 1, and was the 22nd registered.

Central Nervous System Neoplasms

699 studies on the registry are indexed under Central Nervous System Neoplasms; 66 are open to participants now.

Browse Central Nervous System Neoplasms studies →

Open to participants now

1 of the 23 studies testing irinotecan in Central Nervous System Neoplasms is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About irinotecan

Irinotecan: first FDA approval 1996 (CAMPTOSAR), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 57 Central Nervous System Neoplasms studies recruiting now, 35 (61%) set no upper age limit and 19 (33%) stop at 75 or younger; 35 take children under 18; 6 take healthy volunteers.

This study: 1 Year to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing irinotecan in Central Nervous System Neoplasms, or all of them as a file.
02

Study summary

An early phase 1 for pediatric patients with recurrent or progressive CNS malignancies

Read the detailed description

This clinical trial is a early phase 1, open label, single center, single arm study of the combination of intravenously administered SGT-53 and irradiation and/or chemotherapy in pediatric patients with recurrent or progressive CNS malignancies. The objective of the study is to establish the safety and feasibility of administration of SGT-53 in conjunction with conventional radiotherapy and/or chemotherapy in children with recurrent or refractory CNS malignancies.

03

Conditions studied

  • Childhood CNS Tumor

Keywords

  • Childhood CNS tumor
  • Recurrent CNS malignancies
  • Progressive CNS malignancies
  • Refractory CNS malignancies
04

Who can participate

Ages eligible
1 Year to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have a recurrent, progressive, or CNS for which there are not known curative options. Low-grade glioma, craniopharyngioma, and other non-malignant CNS tumors are excluded.
  • Tumor must be measureable, defined as a tumor that can be accurately measured in two perpendicular dimensions on MRI.
  • Patients with disease are eligible but must have at least one target lesions which is measurable.
  • Patients must have available archival (formalin-fixed paraffin embedded) or fresh tumor tissue for correlative studies.
  • Patients must be >1yrs and \<21 years of age.
  • Must have recovered from all surgical interventions prior to the start of the Radiation and Chemotherapy Phases.
  • Patients must have recovered from the acute effects of prior therapy.
  • There is a maximum of 3 previous myelosuppressive therapy regimens. However, there is no maximum number of therapeutic courses.
  • Patients must have received their last dose of known myelosuppressive therapy at least three (3) weeks prior to receipt of SGT-53.
  • Patients must have received their last dose of biological agent >7 days prior to receipt of SGT-53.
  • Patients must be far enough from previous irradiation that in the opinion of a radiation oncologist using standard fractionation is deemed to be reasonable from a clinical standard of care perspective.
  • Patients who are receiving dexamethasone or other must be on a stable or decreasing dose for at least one (1) week prior to enrollment.
  • Patients must have received their last dose of any short acting growth factor at least one week prior to treatment, for long acting or pegylated growth factors, the last dose must be at least two (2) weeks prior to start of treatment.
  • Patients with neurologic deficits must have deficits that have been stable in grade for a minimum of one week prior to enrollment.
  • Performance status ( PS for >16yrs, or Lansky PS for \<16yrs) assessed within two weeks must be >50.
  • Patients must have normal organ and marrow function.
  • All patients of childbearing or child fathering potential must be willing to use an acceptable form of while being treated on this study.
  • Female patients must not be pregnant or nursing. Female patients must also have a negative serum pregnancy test at the time of enrollment.
  • Patient and/or guardian have the ability to understand and the willingness to sign a written document according to institutional guidelines.

Exclusion criteria

Exclusion Criteria:

  • Patients with any unrelated systemic illness (serious infection or significant cardiac, pulmonary, hepatic, or other organ dysfunction) that is likely to interfere with ability to tolerate study therapy or study procedure results.
  • Patients with low-grade gliomas, craniopharyngioma, or extracranial tumors with .
  • Patients who are receiving any other drug therapy.
  • Patients who require therapeutic anti-coagulation.
  • Patients who in the opinion of the investigator cannot adhere to protocol requirements.
  • Patients with history of clinically significant clot or hemorrhage are eligible but will not receive bevacizumab during chemotherapy regimen.
  • Unavailability of the chemotherapy due to insurance coverage or other logistical issues is an ineligibility criterion.
  • Patients may not be on therapy, including (with the exception of physiologic replacement, defined as 0.75mg/m2/day) at time of enrollment. However, patients who require intermittent use of bronchodilators or local steroid injections will not be excluded from the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    SGT-53 with radiation or drugs

    Radiation phase: SGT-53 will be given at 2.1 mg DNA/m2 twice weekly for the first week of radiation therapy, and then increase to 2.8 mg DNA/m2 twice weekly. Radiation therapy will be administered as per clinical care, with a target of fifteen (15) fractions, but patients with other clinically-determined radiation plans will be allowed. Chemotherapy phase: SGT-53 will be administered at the highest tolerated dose given during radiation phase. Irinotecan will be given at a dose of 50mg/m2/dose IV daily for five days in a 4-week cycle. Temozolomide will be given at a dose of 100mg/m2 PO daily for five days in a 4-week cycle and bevacizumab will be given at a dose of 10mg/kg IV every two weeks in a 4-week cycle.

    Genetic: SGT-53 · Radiation: Radiation · Drug: Irinotecan · Drug: Temozolomide · Drug: Bevacizumab

Interventions

  • GeneticSGT-53

    2.1 mg DNA/m2 or 2.8 mg DNA/m2 twice weekly

  • RadiationRadiation

    Standard radiation plan

  • 50mg/m2/dose IV daily for five days in a 4-week cycle

    Also known as: Camptosar, Onivyde

  • 100mg/m2 PO daily for five days in a 4-week cycle

    Also known as: Temodar

  • 10mg/kg IV every two weeks in a 4-week cycle

    Also known as: Avastin

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events

    An adverse event (AE) was any untoward medical occurrence that began or worsened in grade after the start of study drug through 30 days after the last dose. The safety will be assessed by the number and severity of any AE or serious adverse events (SAE) experienced by the patients, and by their relationship to the study drug SGT-53 (e.g. definitely, probably, possibly, unlikely or unrelated). Severity will be graded according to NCI CTCAE version 4.0.

    Time frame: up to 13 months

Secondary outcomes

  1. Response Rate

    The response rate will be calculated from the percentage of patients whose cancer shrinks or disappears after treatment.

    Time frame: 36 months

  2. Duration of Response

    The duration of response will be the time calculated from documentation of tumor response as indicated by response criteria, to disease progression.

    Time frame: 36 months

  3. Overall Survival

    Overall survival will be calculated from date of original diagnoses to death and also from the date of study registration to death.

    Time frame: 36 months

  4. Progressive-Free Survival (PFS)

    PFS will be calculated at all times during follow-up, with particular interest in the 6-month time point. Progression free survival will be calculated from date of first treatment to the date of first observation of progressive disease, non-reversible neurological progression or increasing steroid requirements (applies to stable disease only), death due to any cause, or early discontinuation of treatment.

    Time frame: 36 months

  5. Characterization of Phenotype of Patients

    Tissue will be obtained from each enrolling patient for subsequent testing for TP53 pathway functionality, including assessment of mdm2, p21, and other mutation or expression alterations. This analysis will also include measures of commonly assessed polymorphisms, including MGMT methylation assessment, ATRX mutation among others.

    Time frame: 4-5 days

  6. Feasibility of Droplet PCR Assays to Monitor for Tumor Burden

    Droplet PCR will be used to assess for the presence of circulating tumor DNA

    Time frame: 12 months

07

Study locations

1 site
  • Children's National Medical Center
    Washington D.C., District of Columbia 20010, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Jun 2022, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2018
First posted
Jun 13, 2018
StartActual
Jun 1, 2022
Primary completionActual
Jun 1, 2022
CompletionActual
Jun 1, 2022
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03554707
Lead sponsor
SynerGene Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 13, 2018
Start date
Jun 1, 2022
Primary completion
Jun 1, 2022
Completion
Jun 1, 2022
Last update
May 8, 2026

Study contacts

Eugene Hwang, MD
principal investigator · Children's National Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Irinotecan · Temozolomide · Bevacizumab

Start the discussion